Carregant...

Determinants of Human Immunodeficiency Virus Type 1 Baseline Susceptibility to the Fusion Inhibitors Enfuvirtide and T-649 Reside outside the Peptide Interaction Site

The peptide fusion inhibitor (PFI) enfuvirtide is the first of a new class of entry inhibitors to receive FDA approval. We previously determined the susceptibility of 55 PFI-naïve-patient isolates to enfuvirtide and a second peptide inhibitor, T-649. Seven of the 55 viral isolates were insusceptible...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Heil, Marintha L., Decker, Julie M., Sfakianos, Jeffrey N., Shaw, George M., Hunter, Eric, Derdeyn, Cynthia A.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2004
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC434069/
https://ncbi.nlm.nih.gov/pubmed/15220433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.78.14.7582-7589.2004
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!